Press Releases

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14, 2026

Replimune Announces Pricing of $150 Million Underwritten Offering

August 10, 2026

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

August 6, 2026

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

July 30, 2026

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

June 29, 2026

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

June 26, 2026

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 31, 2026

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026